All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

FDA grants fast track designation to CB-011 for the treatment of RRMM

Apr 28, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM

On April 2023, the U.S. Food and Drug Administration (FDA) granted fast track designation to CB-‍011, an allogeneic anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, for the treatment of relapsed/refractory multiple myeloma.1

CB-011 is a genetically-engineered CAR T cell edited using CRISPR hybrid RNA-DNA.1 These edits include inserting the anti-BCMA CAR into the T cell, removing the beta-2 microglobulin protein, and inserting a beta-2 microglobulin human leukocyte antigen fusion protein.2 The engineering of this therapy aims to improve CAR T-cell persistence and antitumor response through the inhibition of T- and NK-mediated immune rejection.1

CB-011 is currently being evaluated as part of the CaMMouflage phase I trial (NCT05722418). This trial is recruiting patients in the United States who have received at least three prior treatments (including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody) and have not received any previous CAR T-cell therapy. CaMMouflage has two primary outcomes:

  • Part A, dose escalation; aims to establish the optimal therapeutic dosage.
  • Part B, the expansion phase; records overall response rates to indicate efficacy in the treatment of relapsed/refractory multiple myeloma. Part B data will be evaluated using the International Myeloma Working Group (IMWG) response criteria.3

  1. Caribou Biosciences. Caribou Biosciences announces FDA granted fast track designation to CB-011, an allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma. Published Apr 4, 2023. Accessed Apr 24, 2023.
  2. Caribou Biosciences. Next-generation allogeneic cell therapies. Accessed Apr 24, 2023.
  3. CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage). Updated Mar 2, 2023. Accessed Apr 24, 2023.


Subscribe to get the best content related to multiple myeloma delivered to your inbox